Market Overview

The Cortexyme IPO: What You Need To Know

The Cortexyme IPO: What You Need To Know

Four new biotechs hit the market May 9. Here’s one of them.


Cortexyme, Inc. will issue more than 4.41 million shares on the Nasdaq under ticker CRTX, according to the firm’s S-1 filing. Priced between $16 and $18, the offering represents 17 percent of outstanding shares and is expected to bring in about $91.33 million.

Underwriters include Bank of America Merrill Lynch and Credit Suisse.

The company qualifies as an emerging growth company under the U.S. JOBS Act, which exempts management from certain SEC disclosure requirements.

Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here

The Company

Cortexyme develops therapies for neurodegenerative diseases by targeting Porphyromonas gingivalis. The bacterial pathogen has been found in the brains of more than 90 percent of Alzheimer’s patients, according to the firm’s prospectus.

Its lead candidate, COR388, entered Phase 2/3 clinical trials in April for treatment of Alzheimer’s disease. Management expects top-line results by the end of 2021. Cortexyme maintains the rights to the drug and holds a U.S. patent for exclusive development through 2035.

The Finances

In 2018, Cortexyme recorded a net loss of $12.48 million. The previous year saw a loss of $12.24 million. The firm has not yet generated revenue.

Operations have so far been supported by investors such as Pfizer Inc. (NYSE: PFE), Takeda Pharmaceutical Co Ltd (NYSE: TAK), Verily Life Sciences and Sequoia Capital.

Verily Life Sciences is owned by Alphabet, parent company of Google (NYSE: GOOG).

Related Links:

Cortexyme Elects Christopher J. Senner to Its Board of Directors

Cortexyme Sees 4.4M Share IPO Prices $16-$18/Share

Posted-In: News Health Care Previews IPOs Trading Ideas General Best of Benzinga


Related Articles (CRTX + GOOG)

View Comments and Join the Discussion!

Q3 Earnings Outlook For Prospect Capital

Q1 Earnings Preview For Albemarle